Compartment-Specific CD8 Infiltration and Disease-Specific Survival in Resected Ampullary Adenocarcinoma
Steve E. Kalloger, Christine Chow, Dongxia Gao, Katy Milne, James T. Topham, Joanna M. Karasinska, Brad H. Nelson, Daniel J. Renouf, John Aird, David F. Schaeffer · 2026
Read Compartment-Specific CD8 Infiltration and Disease-Specific Survival in Resected Ampullary Adenocarcinoma by Steve E. Kalloger, Christine Chow, Dongxia Gao, Katy Milne, James T. Topham, Joanna M. Karasinska, Brad H. Nelson, Daniel J. Renouf, John Aird, David F. Schaeffer (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13625618.txt.
Description
Ten researchers in Canada test immune markers in a rare bile duct cancer in a 2026 paper. Ampullary adenocarcinoma is uncommon, and its immune profile was barely charted. The team stained resected tumors from ninety-nine patients treated between 1984 and 2013 and linked the patterns to disease specific survival.
Repair deficiency appeared in 37.4 percent of tumors, and most evaluable tumors scored positive for the PD-L1 marker. Killer T cells inside the tumor layer appeared in under a quarter of cases. Neither marker grade nor repair status tracked survival on simple tests. In an adjusted model, inner T cell presence cut the disease hazard by more than half, though a sensitivity check stayed shy of significance.
Catalog record
| CREATOR | Steve E. Kalloger, Christine Chow, Dongxia Gao, Katy Milne, James T. Topham, Joanna M. Karasinska, Brad H. Nelson, Daniel J. Renouf, John Aird, David F. Schaeffer |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |